Last reviewed · How we verify

Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]

Massachusetts General Hospital · FDA-approved active Small molecule

Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] is a Direct-acting antiviral (DAA) combination Small molecule drug developed by Massachusetts General Hospital. It is currently FDA-approved for Chronic hepatitis C virus (HCV) infection, all genotypes, treatment-naïve and treatment-experienced patients, HCV infection in patients with compensated cirrhosis.

Glecaprevir and pibrentasvir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS3/4A protease and NS5A protein, respectively, blocking viral replication.

Glecaprevir and pibrentasvir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS3/4A protease and NS5A protein, respectively, blocking viral replication. Used for Chronic hepatitis C virus (HCV) infection, all genotypes, treatment-naïve and treatment-experienced patients, HCV infection in patients with compensated cirrhosis.

At a glance

Generic nameGlecaprevir / Pibrentasvir Oral Tablet [Mavyret]
SponsorMassachusetts General Hospital
Drug classDirect-acting antiviral (DAA) combination
TargetHCV NS3/4A protease and NS5A protein
ModalitySmall molecule
Therapeutic areaVirology / Hepatology
PhaseFDA-approved

Mechanism of action

Glecaprevir is a pangenotypic NS3/4A protease inhibitor that prevents HCV polyprotein processing, while pibrentasvir is an NS5A inhibitor that disrupts viral RNA replication and assembly. Together, they provide potent inhibition of HCV across all major genotypes with a high barrier to resistance.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]

What is Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]?

Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] is a Direct-acting antiviral (DAA) combination drug developed by Massachusetts General Hospital, indicated for Chronic hepatitis C virus (HCV) infection, all genotypes, treatment-naïve and treatment-experienced patients, HCV infection in patients with compensated cirrhosis.

How does Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] work?

Glecaprevir and pibrentasvir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS3/4A protease and NS5A protein, respectively, blocking viral replication.

What is Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] used for?

Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] is indicated for Chronic hepatitis C virus (HCV) infection, all genotypes, treatment-naïve and treatment-experienced patients, HCV infection in patients with compensated cirrhosis.

Who makes Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]?

Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] is developed and marketed by Massachusetts General Hospital (see full Massachusetts General Hospital pipeline at /company/massachusetts-general-hospital).

What drug class is Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] in?

Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] belongs to the Direct-acting antiviral (DAA) combination class. See all Direct-acting antiviral (DAA) combination drugs at /class/direct-acting-antiviral-daa-combination.

What development phase is Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] in?

Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] is FDA-approved (marketed).

What are the side effects of Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]?

Common side effects of Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] include Headache, Fatigue, Diarrhea, Nausea, Asthenia.

What does Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] target?

Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] targets HCV NS3/4A protease and NS5A protein and is a Direct-acting antiviral (DAA) combination.

Related